Free cash flow deficits narrowed 80% from $12.1M in 2024Q1 to $2.4M in 2026Q2 with zero capex throughout, as cumulative operating cash outflow of $71.8M trailed the $92.0M cumulative net loss by $20.2M through non-cash add-backs and $6.6M of cumulative working capital contributions.
Galectin Therapeutics Inc. (GALT) cash flow statement — 26-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Cash from Operations | -14.61M | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M | -20.6M | -10.85M | -10.18M | -15.89M | -16.41M | -16.98M | -12.43M | -7.48M | -7.5M | -5.68M | -3.1M | -3.89M | -4.67M | -5.48M | -6.76M | -6.13M | -6.33M | -4.15M | -2.98M | -1.8M | -90K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 201.59% | 42.84% | -26.7% | -6.15% | -27.76% | -17.99% | -89.91% | -6.57% | 35.95% | 3.15% | 3.38% | -36.67% | -66.03% | 0.21% | -32.14% | -82.98% | 20.2% | 16.68% | 14.92% | 18.85% | -10.28% | 3.25% | -52.52% | -39.21% | -65.76% | -1899.23% | - |
| Net Income | -23.19M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M | -23.46M | -13.29M | -13.9M | -16.23M | -21.44M | -20.03M | -15.79M | -12.09M | -9.9M | -10.91M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190K |
| Depreciation & Amortization | 87K | 53K | 37K | 33K | 32K | 41K | 36K | 35K | 1K | 1K | 7K | 7K | 10K | 12K | 9K | 9K | 12K | 37K | 49K | 64K | 67K | 81K | 81K | 89K | 211.18K | 159.47K | 0 |
| Stock-Based Compensation | 2.79M | 1.66M | 2.45M | 2.26M | 2.87M | 2.08M | 1.8M | 1.68M | 4.45M | 1.1M | 2.48M | 3.4M | 4.07M | 3.79M | 2.79K | 3.25M | 1.94M | 1.61M | 697K | 0 | 0 | 0 | 0 | 0 | 147.32K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -616K | -416K | -23K | 0 | -618.87K | 0 | 0 | 0 |
| Other Non-Cash Items | 6.88M | 4.64M | 512K | 1.13M | -147K | 351K | 87K | 87K | 347K | 45K | 0 | 0 | 400K | 0 | 3.02M | 524K | 1.26M | 1.53M | -2.13M | 4.32M | -2.81M | 66K | 171K | 1.25M | 204.27K | 1.85M | 20K |
| Working Capital Changes | -1.18M | 609K | 2.28M | 4.68M | 4.97M | 3.75M | 942K | 641K | -1.07M | -804K | 2.54M | -363K | -1.12M | 803K | -626K | 1.46M | -683K | 399K | -126K | 184K | -406K | 293K | 595K | 0 | 133K | 160.12K | 80K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 234K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.73M | -6.04M | -2.07M | 2.67M | 4.24M | 3.69M | 2.54M | 997K | -1.09M | -812K | 2.42M | -342K | -783K | 0 | 0 | 1.27M | -140K | 125K | 0 | 111K | -528K | 374K | 627K | 28.62K | 157.09K | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K | 64K | 64K | -15K | 0 | 0 | 9K | 4.95M | -5.24M | -111K | -69K | -105.7K | -138.28K | -171.12K | -10K |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5K | -5K | -5K | 0 | 0 | -2K | -42K | -98K | -21K | -23K | -39.36K | -109.3K | -123.7K | -10K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K | 400K | 69K | 69K | -10K | 0 | 0 | 11K | -11K | -138K | -90K | -46K | -66.34K | -28.98K | -47.42K | 0 |
| Cash from Financing | 14.79M | 26.48M | 31.23M | 40.03M | 10M | 36.81M | 263K | 50.08M | 15.38M | 3.58M | 5.92M | 13.7M | 31.46M | 8.61M | 10.4M | 6.2M | 8.74M | 3.82M | 3.65M | 1.08M | 8.3M | 0 | 9.5M | 9.94M | 3.55M | 3.26M | 300K |
| Debt Issued (Net) | 10M | 21M | 30M | 30M | 10M | 30M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | -555K | 8.3M | 0 | 0 | 0 | -86K | 0 | 0 |
| Equity Issued (Net) | 4.09M | 5.47M | 1.23M | 0 | 0 | 6.81M | 263K | 50.47M | 15.38M | 3.58M | 5.92M | 13.7M | 29.34M | 3.83M | 10.4M | 130K | 3.54M | 4.02M | 3.46M | 0 | 0 | 0 | 9.5M | 9.94M | 3.64M | 2.22M | 0 |
| Dividends Paid | -62K | 0 | -91K | 0 | 0 | -171K | -137K | -394K | -915K | -1.23M | -741K | -943K | -943K | 0 | 0 | -1.54M | -2.07M | -209K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K |
| Other Financing | 764K | 0 | 91K | 10.03M | 0 | 171K | 137K | 0 | 915K | 1.23M | 741K | 943K | 3.07M | 4.78M | 0 | 7.6M | 7.28M | 9K | 0 | 1.64M | 0 | 0 | 0 | 442 | 0 | 1.04M | 300K |
| Net Change in Cash | 181K | 2.6M | -10.54M | 7.07M | -21.06M | 12.51M | -20.34M | 39.23M | 5.2M | -12.31M | -10.48M | -3.28M | 18.64M | 1.13M | 2.97M | 506K | 5.64M | -67K | -1M | 546K | -3.69M | -6.24M | 3.1M | 5.69M | 430.06K | 1.29M | 210K |
| Free Cash Flow | -14.61M | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M | -20.6M | -10.85M | -10.18M | -15.89M | -16.41M | -16.98M | -12.43M | -7.49M | -7.5M | -5.68M | -3.1M | -3.89M | -4.67M | -5.53M | -6.86M | -6.15M | -6.36M | -4.19M | -3.09M | -1.97M | -100K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 52.29% | 42.84% | -26.7% | -6.15% | -27.76% | -17.99% | -89.91% | -6.57% | 35.95% | 3.15% | 3.38% | -36.67% | -65.92% | 0.21% | -32.11% | -83.14% | 20.2% | 16.71% | 15.53% | 19.4% | -11.5% | 3.27% | -51.64% | -35.56% | -56.92% | -1870.42% | - |
| FCF per Share | -0.16 | -0.37 | -0.67 | -0.55 | -0.52 | -0.42 | -0.36 | -0.21 | -0.26 | -0.45 | -0.56 | -0.70 | -0.57 | -0.44 | -0.50 | -0.47 | -0.33 | -0.48 | -0.60 | -0.85 | -1.44 | -1.35 | -1.48 | -1.18 | -1.13 | -0.87 | -0.05 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.77x | 0.89x | 0.80x | 0.80x | 0.80x | 0.88x | 0.82x | 0.73x | 0.98x | 0.77x | 0.85x | 0.79x | 0.62x | 0.78x | 0.52x | 0.55x | 0.52x | 1.48x | 0.58x | 2.12x | 0.94x | 0.88x | 0.85x | 0.81x | 0.45x | 0.47x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying GALT stock.
Galectin Therapeutics Inc. (GALT) generated $-23.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Galectin Therapeutics Inc. (GALT) reported negative free cash flow of $23.9M in 2025, indicating capital requirements exceeded cash from operations.
Galectin Therapeutics Inc. (GALT) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Runway Unverified Against Persistent Burn
Metrics are mathematically derived from official filings.
Cash Losses Trail Reported Losses
Across ten quarters, cumulative operating cash outflow of $71.8M trailed the $92.0M cumulative net loss, per Galectin's reported cash flow statements, with quarterly OCF/NI ratios from 0.27 to 1.10, indicating reported losses overstate cash consumption through non-cash add-backs.
The pattern suggests the income statement loss is inflated relative to cash usage, most visibly in 2026Q2, where a $9.1M net loss against $2.4M of operating outflow appears to reflect the below-line items flagged in the income statement review rather than worsening operations. However, the relationship inverted in 2024Q1, 2024Q4, and 2025Q4, when cash outflow exceeded the book loss, so the earnings-quality cushion is inconsistent rather than structural and investors should not extrapolate the 0.27 ratio forward.
Free Cash Flow Deficit Narrows Sharply
Galectin's quarterly free cash flow deficit narrowed 80%, from $12.1M in 2024Q1 to $2.4M in 2026Q2, per its ten-quarter cash flow series, a trajectory driven by R&D contraction rather than revenue, as FCF equals operating cash flow with zero capital expenditure.
The improvement tracks the 81% R&D compression identified in the income statement analysis, implying the burn trajectory depends on continued cost discipline rather than a self-funding commercial event. The last four quarters averaged roughly $4.0M of free cash outflow versus $10.4M per quarter across 2024, so if cost contraction stalls at the current $4.0M operating loss level, the burn may flatten instead of declining further.
No Capital Spending Distorts FCF Read
Galectin recorded zero capital expenditure in each of the ten quarters through 2026Q2, as reported in Galectin's cash flow statements, leaving free cash flow identical to operating cash flow and showing no manufacturing or facility build-out consuming cash.
With no capital outlay, quarterly depreciation of just $4K to $41K confirms an essentially fixed-asset-free cost base, meaning there is no maintenance-capex cushion to trim and no growth-capex overhang to fund through financing. Any scale-up capital program ahead of a regulatory or commercial milestone would therefore appear as a new, discrete line item, and investors may wish to monitor capex for early signs of that transition.
Working Capital Softens the Burn
Quarterly working capital contributed a cumulative $6.6M of cash over ten quarters, based on Galectin's quarterly cash flow statements, with swings from negative $2.3M in 2024Q1 to positive $2.5M in 2026Q2, partially offsetting the underlying operating cash burn.
Because revenue is nil throughout the period, these swings cannot reflect receivables or inventory cycling and appear more consistent with payables, accrual, and prepaid-timing movements around trial and vendor payments. Since the cumulative $6.6M inflow materially softens the reported burn, the improvement in free cash flow should not be read as entirely expense-driven, nor should this benefit be assumed to repeat on a predictable basis.
Earnings Gap Exceeds Disclosed Add-Backs
Over ten quarters through 2026Q2, Galectin's cumulative net losses of $92.0M exceeded cumulative operating cash outflow of $71.8M by $20.2M, per Galectin's cash flow filings, while disclosed stock compensation totaled only $5.8M, suggesting other non-cash items or accrual timing fill much of the gap.
Roughly $14.4M of the divergence therefore remains unexplained by the stock compensation line alone, which warrants investigation into warrant revaluations, derivative marks, or deferred-cost reversals in the full statements. The consistent direction of the gap implies reported losses overstate near-term cash consumption, but it does not reduce the aggregate capital consumed or the resulting dependence on external funding.
Cash Statement Omits Runway Visibility
As Galectin's cash flow statements show, only a $61K dividend payment and no buyback or acquisition outflows appear across ten quarters, yet without a disclosed cash balance, the runway implied by the current $2.4M quarterly burn cannot be verified from these figures.
Because financing inflows, debt movements, and the ending cash position sit outside this dataset, the number of quarters the company can sustain even the reduced burn profile is an open question investors should not infer from operating trends alone. Additionally, $5.8M of stock compensation was added back to reach operating cash flow while any accompanying equity issuance is not visible here, so the dilution paired with the burn appears understated by these cash figures.